Can moboxetinib treat kidney cancer?

Mobocertinib is not a standard treatment for kidney cancer. For the treatment of kidney cancer, commonly used methods include surgical resection, radiotherapy, chemotherapy, targeted therapy and immunotherapy. The specific treatment plan should be determined by the doctor based on the patient's individual situation and tumor characteristics.

Mobosetinib is an oral epidermal growth factor receptor (EGFR) inhibitor that targets EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non-small cell lung cancer and was evaluated in a Phase 1/2 dose escalation/expansion trial. Dose escalation determined 160 mg daily as the recommended Phase 2 dose and maximum tolerated dose. The most common treatment-related adverse events of any grade were diarrhea, nausea, rash, and vomiting, with diarrhea being the more common adverse event. Among 28 patients who received 160 mg daily of EGFRex20ins, the investigator-assessed confirmed response rate was 43%, the median duration of response was 14 months, and the median progression-free survival was 7.3 months. Mobocitinib showed antitumor activity in patients with multiple EGFRex20ins variants and its safety profile was consistent with other EGFR inhibitors.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.